Comparative Pharmacology
Head-to-head clinical analysis: NEPHRAMINE 5 4 versus TRAVASOL 10 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHRAMINE 5 4 versus TRAVASOL 10 W O ELECTROLYTES.
NEPHRAMINE 5.4% vs TRAVASOL 10% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Travasol 10% w/o electrolytes is a parenteral nutrition solution containing essential and non-essential amino acids. The amino acids provide substrates for protein synthesis, thereby supporting tissue repair, growth, and maintenance. The solution also provides a source of nitrogen and caloric replacement.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
10% amino acid solution administered intravenously via central line at 0.5-1.0 g amino acids/kg/day, not to exceed 2.5 g/kg/day; typical infusion rate 50-125 mL/hr.
None Documented
None Documented
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
The terminal elimination half-life of infused amino acids is approximately 1-2 hours, reflecting rapid metabolism and clearance. Clinical context: Steady state is achieved within 1-2 hours of continuous infusion.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Amino acids are primarily metabolized; nitrogen is excreted renally as urea (∼85-90%), with small amounts in feces (∼5%) and minimal biliary elimination. Electrolytes are excreted renally, with excretion proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution